Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)
Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:10PM CST
Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable opinion for the treatment of adult men suffering from Peyronie's disease.
ENDP: 72.10 (+0.34), CBST: 100.29 (-0.09), AUXL: 34.40 (+0.18), BIOD: 1.36 (-0.04)
Jim Cramer on the Markets: Some Stocks You Just Can't Ignore
at The Street - Tue Dec 23, 9:03AM CST
And stop chasing stocks that won't let you in.
FDX: 176.42 (-0.52), MMM: 166.96 (+0.09), SWKS: 74.32 (+0.92), NKE: 96.29 (+0.32), HON: 101.96 (-0.02), DIS: 94.42 (-0.27), BA: 131.24 (+1.21), MS: 38.81 (-0.14), AA: 15.77 (+0.04), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), COST: 143.65 (-0.50), CVS: 97.89 (+0.02), MCD: 93.83 (-0.39), GOOGL: 536.93 (-1.84), ROST: 92.72 (-0.60)
Watch for Cubist Pharmaceuticals to Potentially Pullback After Gaining 1.82% Yesterday
Comtex SmarTrend(R) - Mon Dec 22, 3:53PM CST
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $100.15 to a high of $100.97. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $99.25 on volume of 6.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CBST: 100.29 (-0.09)
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)
Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie
PR Newswire - Mon Dec 22, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AstraZeneca (NYSE: AZN), Advaxis (NASDAQ: ADXS), Radius Health (NASDAQ: RDUS), Cubist (NASDAQ: CBST), and AbbVie (NYSE: ABBV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
RDUS: 37.17 (+0.11), ADXS: 7.57 (+0.50), CBST: 100.29 (-0.09), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)
Merck begins tender offer to acquire Cubist
M2 - Mon Dec 22, 6:43AM CST
Healthcare company Merck (NYSE:MRK) said on Friday that its subsidiary has started a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST).
CBSTZ: 0.06 (+0.01), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
FDA approves Cubist's Zerbaxa
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 5:35PM CST
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Cubist Announces FDA Approval of New Antibiotic ZERBAXA(TM) (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
Business Wire - Fri Dec 19, 5:08PM CST
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today the U.S. Food and Drug Administration (FDA) approved ZERBAXA(TM) (ceftolozane/tazobactam) for the treatment of adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) caused by designated susceptible Gram-negative bacteria.
CBST: 100.29 (-0.09)
Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 4:20PM CST
Merck (MRK) acquired Swiss biotech privately held company, OncoEthix, and added a promising experimental early-stage candidate, OTX015, to its oncology portfolio.
AGN: 210.12 (+0.95), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86)
Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:19PM CST
Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the treatment of complicated intra-abdominal infection.
JNJ: 104.59 (+0.31), TTPH: 38.86 (+0.53), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Cubist Pharmaceuticals (CBST) Showing Signs Of Being A Momo Momentum Stock
at The Street - Fri Dec 19, 8:45AM CST
Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a momo momentum candidate
CBST: 100.29 (-0.09)
Merck Begins Tender Offer to Acquire Cubist
Business Wire - Fri Dec 19, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire Cubist.
CBSTZ: 0.06 (+0.01), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:30PM CST
A report from Bloomberg indicated that the Shire is considering a potential acquisition of the NPS Pharma.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)
PDUFA date approaches for Cubist antibiotic combo
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:29AM CST
CBST: 100.29 (-0.09)
Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 38.86 (+0.53), ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Shares of CBST Up 46.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 17, 4:47PM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 2 months, Cubist Pharmaceuticals has returned 46.52% as of today's recent price of $97.81.
CBST: 100.29 (-0.09)
Cubist Pharmaceuticals: An Extraordinary Arbitrage Opportunity
Shareholder Boar - at Seeking Alpha - Wed Dec 17, 10:26AM CST
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.69 (+0.01), CBST: 100.29 (-0.09), SPHS: 0.46 (+0.02), CCXI: 6.64 (-0.04), ALXN: 181.96 (+3.09), EXEL: 1.29 (-0.01)